ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement on Development of Pharmaceutical Formulation for IMX101

ProJect Pharmaceutics has signed a development agreement with ImevaX, a spin-off project from the research group of Prof. Dr Markus Gerhard from the Technische Universität München, Institute for Medicinal Microbiology, Immunology and Hygiene, aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multicomponent vaccine, making the formulation development particularly challenging.

The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimised protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analysing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing.

Promising formulation candidates have successfully been evaluated and are continuously optimised within the development programme since its launch in mid 2013.

Financial terms of the current agreement are not disclosed.